Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jazz Pharmaceuticals PLC (JAZZ : NSDQ)

• Company Description    Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'. Number of Employees: 2,800

• Price / Volume Information    Yesterday's Closing Price: $128.46 Daily Weekly Monthly 20 Day Moving Average: 682,018 shares Shares Outstanding: 60.66 (millions) Market Capitalization: $7,792.23 (millions) Beta: 0.24 52 Week High: $148.06 52 Week Low: $95.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.10% 8.12% 12 Week 18.68% 7.75% Year To Date 4.31% -6.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD - DUBLIN,L2 D04 E5W7 IRL ph: 011-353-1634-7800 fax: 353-1634-7850 investorinfo@jazzpharma.com http://www.jazzpharma.com

• General Corporate Information    Officers Bruce C. Cozadd - Chief Executive Officer; Chairman and Director Philip L. Johnson - Executive Vice President and Chief Financial Offic Patricia Carr - Senior Vice President Jennifer E. Cook - Director Patrick G. Enright - Director Peer Information Jazz Pharmaceuticals PLC (CORR.) Jazz Pharmaceuticals PLC (RSPI) Jazz Pharmaceuticals PLC (CGXP) Jazz Pharmaceuticals PLC (BGEN) Jazz Pharmaceuticals PLC (GTBP) Jazz Pharmaceuticals PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G50871105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 60.66 Most Recent Split Date: (:1) Beta: 0.24 Market Capitalization: $7,792.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $4.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.70 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 9.47% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: 75.43 Trailing 12 Months: 41.57 PEG Ratio: 7.97 Price Ratios Price/Book: 2.10 Price/Cash Flow: 4.23 Price / Sales: 1.91 EPS Growth vs. Year Ago Period: -294.22% vs. Previous Quarter: -1,611.67% Sales Growth vs. Year Ago Period: 2.14% vs. Previous Quarter: 16.47% ROE 06/30/25 - 5.02 03/31/25 - 26.62 12/31/24 - 29.88 ROA 06/30/25 - 1.73 03/31/25 - 9.14 12/31/24 - 10.01 Current Ratio 06/30/25 - 1.62 03/31/25 - 3.38 12/31/24 - 4.46 Quick Ratio 06/30/25 - 1.37 03/31/25 - 2.97 12/31/24 - 3.99 Operating Margin 06/30/25 - 4.96 03/31/25 - 26.53 12/31/24 - 28.87 Net Margin 06/30/25 - -9.91 03/31/25 - 11.86 12/31/24 - 13.77 Pre-Tax Margin 06/30/25 - -12.51 03/31/25 - 8.91 12/31/24 - 11.56 Book Value 06/30/25 - 61.10 03/31/25 - 67.74 12/31/24 - 67.72 Inventory Turnover 06/30/25 - 0.91 03/31/25 - 0.89 12/31/24 - 0.83 Debt-to-Equity 06/30/25 - 1.17 03/31/25 - 1.28 12/31/24 - 1.48 Debt-to-Capital 06/30/25 - 53.91 03/31/25 - 56.11 12/31/24 - 59.75

Powered by Zacks Investment Research ©